Treats Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive. ANDA 215582, held by Quagen. Aripiprazole.
As of Nov 16, 2026, ANDA 215582 (Aripiprazole), held by Quagen, was first approved by FDA on Oct 22, 2025, with 0 approved supplements and 0 published complete response letters.
Aripiprazole Oral Solution is indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole oral solution is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aripiprazole1MG/ML · solution;oral | Aripiprazole | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters